$科兴生物(SVA)$ Sinovac Biotech reported a sales increase for the second half of 2023, reaching $307.9 million, driven by higher sales of influenza vaccines.
Sinovac expanded its international market access for influenza vaccines with approvals in countries like Pakistan and Chile.
The company's strategic developments in 2023 included successful joint ventures in vaccine production in Türkiye and Latin America, positioning Sinovac as a key player in vaccine R&D and production.